World Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial August 8, 2023
Business “India’s innovation prowess exemplifies local impact with global implications”.- Kris Gopalakrishnan, Past President, CII & Co-Founder, Infosys & Chairman, Axilor Ventures August 7, 2023
